Lincoln Pharmaceuticals posts Rs 11.63 crore profit for Q4

Lincoln Pharmaceuticals announced a slight profit rise for the fourth quarter ending March 31, 2026. Full fiscal year 2025-26 saw over 6 percent growth in consolidated net profit. Revenue from operations also increased year-on-year. The company's board recommended an 18 percent dividend. Lincoln Pharmaceuticals targets Rs 1,000 crore revenue in three years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/76Rj9yd
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6aAjqyO
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Goup CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3WLvRrg
via IFTTT

Read More

Zydus Therapeutics' saroglitazar drug granted priority review by US FDA

Zydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver disease. The company plans to launch saroglitazar in the US in the fourth quarter of fiscal year 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gNGJ9PZ
via IFTTT

Read More

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with chronic hepatitis B.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3KpX2D
via IFTTT

Read More

Wockhardt gets CDSCO nod for Zaynich antibiotic

Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to treat complicated urinary tract infections in adults. The approval follows successful clinical trials. Zaynich shows potential against drug-resistant bacteria. This marks a significant step in combating challenging infections.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JLseqSv
via IFTTT

Read More

India's out-of-pocket healthcare spending drops significantly, govt data shows

Indian families now pay less for healthcare. Out-of-pocket spending fell from 64.2% to 43.4% in ten years. This is due to the government spending more on public health. Government health expenditure as a share of GDP has also increased. Per capita spending on health has grown significantly. This shows a stronger health financing safety net for citizens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5kYMDTZ
via IFTTT

Read More